Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET

Company Participants

Ray Furey - Executive Vice President, General Counsel & Corporate Secretary.

Raul Rodriguez - President & Chief Executive Officer

Dave Santos - Chief Commercial Officer

Lisa Rojkjaer - Chief Medical Officer

Dean Schorno - Chief Financial Officer

Conference Call Participants

Joe Pantginis - H.C. Wainwright

Kalpit Patel - B. Riley Securities

Farzin Haque - Jefferies

Operator

Greetings and welcome to Rigel Pharmaceutical's Financial Conference Call for the Third Quarter 2024. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce our first speaker, Ray Furey, Rigel's Executive Vice President, General Counsel, and Corporate Secretary.

Thank you, Mr. Furey. You may begin.

Ray Furey

Welcome to our third quarter 2024 financial results and business update conference call. The financial press release for the third quarter 2024 was issued a short while ago and can be viewed along with the slides for this presentation in the news and events section of our investor relations site on Rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory and product development.

These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on form 10-K for the year ended December 31st, 2023, and subsequent filings with the SEC including our Q3 quarterly report on form 10-Q on filed with the SEC. Any forward-looking statements are made only as of today's date and we undertake no obligation to update these